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Abstract
Background:  Moxifloxacin is a respiratory fluoroquinolone with a community acquired
pneumonia indication. Unlike other fluoroquinolones used in our healthcare system, moxifloxacin's
urinary excretion is low and thus we hypothesized that increased use of moxifloxacin is associated
with an increase in fluoroquinolone resistance amongst gram negative uropathogens.
Methods: All antibiograms for Gram negative bacteria were obtained for 2000 to 2005. The
defined daily dose (DDD) for each fluoroquinolone was computed according to World Health
Organization criteria. To account for fluctuation in patient volume, DDD/1000 bed days was
computed for each year of study. Association between DDD/1000 bed days for each
fluoroquinolone and the susceptibility of Gram negative bacteria to ciprofloxacin was assessed
using Pearson's Correlation Coefficient, r.
Results:  During the study period, there were 48,261 antibiograms, 347,931 DDD of
fluoroquinolones, and 1,943,338 bed days. Use of fluoroquinolones among inpatients decreased
from 237.2 DDD/1000 bed days in 2000 to 115.2 DDD/1000 bed days in 2005. With the exception
of Enterobacter aerogenes, moxifloxacin use was negatively correlated with sensitivity among all 13
Gram negative species evaluated (r = -0.07 to -0.97). When the sensitivities of all Gram negative
organisms were aggregated, all fluoroquinolones except moxifloxacin were associated with
increased sensitivity (r = 0.486 to 1.000) while moxifloxacin was associated with decreased
sensitivity (r = -0.464).
Conclusion:  Moxifloxacin, while indicated for empiric treatment of community acquired
pneumonia, may have important negative influence on local antibiotic sensitivities amongst Gram
negative organisms. This effect was not shared by other commonly used members of the
fluoroquinolone class.
Background
Antibiotic resistance places a large burden on the health-
care system, with both increased costs and increased mor-
bidity and mortality. Infection with resistant bacteria can
double hospital length of stay and associated costs [1]. As
the problem of antibiotic resistance has grown, awareness
of induction of resistance from antibiotic use has
increased. This concept has most firmly taken root in the
Intensive Care Unit (ICU), where empiric antibiotic regi-
mens have been developed not only for safety and efficacy
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of treatment, but also to prevent the rise of resistant
organisms [2].
The traditional antimicrobial therapy of choice in any cir-
cumstance has been a regimen that is efficacious, safe, and
inexpensive. However, if that regimen induces antibiotic
resistance then efficacy soon suffers. Moxifloxacin is a res-
piratory fluoroquinolone with an indication for commu-
nity acquired pneumonia (CAP). Moxifloxacin's broad
spectrum coverage has also gained the drug indications
for acute bacterial exacerbations of chronic bronchitis,
acute maxillary sinusitis, skin and soft tissue infections,
and more recently complicated intra-abdominal infec-
tions. However, compared to other commonly used fluo-
roquinolones, only 20% of moxifloxacin is excreted into
the urinary tract [3]. We hypothesized that increased use
of moxifloxacin is associated with an increase in fluoro-
quinolone resistance amongst Gram negative organisms.
Methods
This observational study used antibiogram data from a
three hospital healthcare system sharing the same drug
formulary. The quantity and volume of doses of fluoro-
quinolone given over a six year period (2000 to 2005)
were provided by the hospital pharmacy system, and the
number of inpatient hospital bed days were extracted
from central databases. Only deidentified summary data
were provided, and thus this study was exempt from Insti-
tutional Review Board oversight.
The three hospitals include an urban, tertiary care aca-
demic center with 662 beds, an urban community hospi-
tal with 555 beds, and a suburban community hospital
with 200 beds. The academic center treats the majority of
the region's indigent patient population under a tax levy
system. The three hospitals primarily admit adults; those
under the age of 18 are usually treated at the region's chil-
dren's hospital.
Antibiograms are generated by the core laboratory from
inpatient blood cultures, and reported in aggregate on a
yearly basis. Susceptibility to ciprofloxacin is the system's
preferred marker for susceptibility to fluoroquinolones.
Susceptibility to ciprofloxacin was determined by mini-
mum inhibitory concentration (MIC) with an MIC of <1
microgram/ml considered susceptible. All antibiograms
for blood cultures growing Gram negative bacteria were
obtained for each year from 2000 to 2005. Four main
antibiotics in the fluoroquinolone class were used during
the study period: ciprofloxacin, levofloxacin, gatifloxacin,
and moxifloxacin. Gatifloxacin was removed from use
during 2002 secondary to concerns about the side-effect
profile, and was replaced with other respiratory fluoroqui-
nolones.
The defined daily dose (DDD) for each antibiotic was
computed according to World Health Organization crite-
ria to account for variations in IV and PO dosing [4]. To
account for fluctuation in patient volume, DDD/1000 bed
days was computed for each year of study. Association
between DDD/1000 bed days for each FQ and the suscep-
tibility of Gram negative bacteria to ciprofloxacin was
assessed using Pearson's Correlation Coefficient.
Results
During the study period, there were 1,943,338 inpatient
bed days. A total of 48,261 antibiograms for gram nega-
tive bacteria were generated, and 347,931 DDD of fluoro-
quinolones were given. [Additional file 1] shows the
number of susceptible isolates and total isolates for Gram
Defined daily doses for each fluoroquinolone, and for all fluo- roquinolones adjusted for patient volume for each month of  the study (Panel A) Figure 1
Defined daily doses for each fluoroquinolone, and for 
all fluoroquinolones adjusted for patient volume for 
each month of the study (Panel A). The percentage 
contribution of each fluoroquinolone to the total is also 
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negative bacteria for each year of the study. Use of fluoro-
quinolones among inpatients decreased from 237.2
DDD/1000 bed days in 2000 to 115.2 DDD/1000 bed
days in 2005 (Figure 1). Moxifloxacin use increased dur-
ing the period of study, whereas all other fluoroquinolo-
nes showed a decrease in usage. Moxifloxacin use peaked
in 2003–2004, after which the proportion of moxi-
floxacin to total fluoroquinolone usage remained approx-
imately constant.
Table 1 shows the correlations between antibiotic usage
and sensitivity to fluoroquinolones. Sample size was 6 (n
= 1 for each year of study), thus a correlation coefficient
above 0.81 is significant at the 5% level. With the excep-
tion of Enterobacter aerogenes, moxifloxacin use was nega-
tively correlated with sensitivity among all Gram negative
species evaluated. When the sensitivities of Gram negative
organisms were aggregated, all fluoroquinolones except
moxifloxacin were associated with increased sensitivity,
while moxifloxacin was associated with decreased sensi-
tivity (r = -0.636).
Discussion
Our study results show an association between the use of
moxifloxacin in our healthcare system and an increase in
fluoroquinolone resistance amongst Gram negative bacte-
ria. The efficacy of moxifloxacin against S. pneumoniae has
been documented in multiple studies across multiple
patient populations [5-7]. Additionally, moxifloxacin has
documented in vivo efficacy against Gram negative bacte-
ria a variety of body tissues [8,9]. In contrast, moxi-
floxacin is not FDA approved for the treatment of urinary
tract infections, and no published clinical data exists on
moxifloxacin's efficacy in urinary tract infections.
Fluoroquinolones exhibit concentration dependent bac-
tericidal effects, and urine excretion of moxifloxacin is
half that of the next closest fluroquinolone used in our
healthcare system (ciprofloxacin at 43% [3]). Urine con-
centrations after a single dose of moxifloxacin in healthy
volunteers have previously been found to be effective in
vitro against levofloxacin susceptible and moderately sus-
ceptible strains of E. Coli, E. faecalis, and K. pneumoniae but
not P. aeruginosa [10]. However, the relatively low excre-
tion of moxifloxacin into the urine is particularly impor-
tant due to the rising North American MIC90  of
moxifloxacin against E. Coli. The TRUST 11 surveillance
database demonstrated an MIC90 of 32 mcg/ml for moxi-
floxacin against E. Coli.
In addition, in vivo urine bactericidal concentrations may
be much higher then in vitro due to biofilm [3] and pH
effects [10]. Biofilms have been demonstrated to mark-
edly increase needed minimum inhibitory concentrations
(MICs) and a recent study by Rosen et al found filamen-
tous bacteria were common even in healthy women with
uncomplicated cystitis [11]. Additionally, fluoroquinolo-
nes have been shown to have be less active in acidic urine
(pH 5) against E. Coli than in a broth medium [12]. As
fluoroquinolone activity is concentration dependent,
these factors may contribute to a differential in a sub-ther-
apeutic exposure among urinary pathogens between
moxifloxacin and other fluoroquinolones that are
excreted in higher urinary concentrations. Sub-therapeu-
tic exposure may result in selection of fluoroquinolone
resistant among Gram negative bacteria dwelling in the
urinary tract through previously established resistance
mechanisms, such as mutations in DNA gyrase or devel-
opment of efflux pumps [13].
Table 1: Correlation between DDD/1000 bed days and sensitivity to gram negative bacteria by antibiogram (N = 6, years 2000–2005)
Organism DDD/1000 bed days
Ciprofloxacin Levofloxacin Gatifloxacin Moxifloxacin All
Acinetobacter baumanii complex 0.682 0.410 0.681 -0.158 0.775
Citrobacter freundii complex 0.856 0.706 0.482 -0.238 0.906
Citrobacter koseri 0.511 0.645 0.505 -0.970 0.394
Enterobacter aerogenes -0.559 -0.671 -0.627 0.887 -0.529
Enterobacter cloacae 0.956 0.840 0.789 -0.654 0.978
Escherichia coli 0.994 0.873 0.745 -0.666 0.987
Klebsiella oxytoca, Non-ESBL 0.649 0.388 0.509 -0.067 0.709
Klebsiella pneumoniae, Non-ESBL 0.457 0.269 0.364 -0.162 0.442
Morganella morganii 0.769 0.776 0.643 -0.921 0.666
Proteus mirabilis 0.996 0.878 0.651 -0.587 0.984
Providencia stuartii 0.780 0.605 0.726 -0.350 0.872
Pseudomonas aeruginosa -0.119 0.320 -0.417 -0.522 -0.278
Serratia marcescens 0.665 0.584 0.436 -0.602 0.553
All organisms 0.995 0.890 0.670 -0.636 0.978BMC Infectious Diseases 2008, 8:71 http://www.biomedcentral.com/1471-2334/8/71
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An alternative mechanism for increasing resistance among
Gram negative organisms was discussed by von Baum et
al. [14] Their study found a doubling in the incidence of
Gram negative bacteremia among patients given moxi-
floxacin as prophylaxis during neutropenia compared to
historical controls given levofloxacin. It was proposed
that this effect was due to moxifloxacin's superior efficacy
against anaerobes. Elimination of native intestinal flora
causesa loss of intestinal colonization resistance which
may have favored colonization with fluoroquinolone
resistant  E. coli. Joris et al. [15] was able to show an
increase in fluoroquinolone resistant Gram negative
bacilli effect in healthy volunteers exposed to cipro-
floxacin in combination with a drug with good efficacy
against anaerobes, clindamycin. This increase was not
seen in patients on ciprofloxacin alone.
In our health care system, ciprofloxacin is still a primary
treatment for urinary tract infections. The increasing local
resistance of Gram negative bacteria to ciprofloxacin has
important consequences for empiric treatment of urosep-
sis and other Gram negative bacteremias. Further investi-
gations should include microbiological investigation of
the proposed mechanism of increasing resistance, as well
as assessing the effect of outpatient fluoroquinolone pre-
scriptions on resistance within the healthcare system.
Limitations
While our findings demonstrate an association between
increased use of moxifloxacin and sensitivity of gram neg-
ative bacteria to fluoroquinolone, this was a retrospective
review of antibiotic usage and microbial sensitivity. This
study design is incapable of establishing a causal link
between moxifloxacin usage and increasing fluoroqui-
nolone resistance. Also, it is currently thought that fluoro-
quinolone resistance is not significantly influenced by
other antimicrobial agents, and thus analysis was limited
to the fluoroquinolone class. No formal microbiological
studies were undertaken to demonstrate this property
within our healthcare system. Finally, this study only con-
sidered inpatient antibiotic usage and inpatient blood cul-
tures. It is possible that increases in non-moxifloxacin
fluoroquinolone prescriptions to outpatients during the
study period may be confounding the observed relation-
ships.
Conclusion
Moxifloxacin, while indicated for empiric treatment of
respiratory, soft tissue, and intra-abdominal infections, is
associated with a negative influence on local antibiotic
sensitivities amongst Gram negative organisms. This asso-
ciation does not seem to be shared by other commonly
used members of the fluoroquinolone class used by our
healthcare system. Further studies are needed to deter-
mine if there is a causal link between moxifloxacin use
and Gram negative resistance to fluoroquinolones, as well
as the exact mechanism of this increasing resistance.
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